Glenn Saldanha News

Glenmark Pharmaceuticals Tuesday said it is looking at strong growth in the US market and developing a pipeline of innovative products to offset weakness in emerging markets.

Glenmark Pharmaceuticals has received approval for generic Salmecort MDI inhaler used for management of asthma and pulmonary disease from Russia's Ministry of Health.

As many as six out of seven molecules in Glenmark's drug discovery pipeline are currently in the clinical trial stage and the company's R&D spend pegged at 10 percent of sales is expected to be maintained at similar levels for next two years, a top official has said.

Glenmark Pharmaceuticals plans to set up its first manufacturing facility in the US at an estimated investment of over Rs 500 crore to cater to the North American market.